Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novel Sickle Cell Treatment Among 13 New Drugs On Track For EU Approval

Executive Summary

A first-of-its-kind drug for uterine fibroids and a new monoclonal antibody treatment for COVID-19 are among several new drugs recommended for pan-EU approval this month.

You may also be interested in...



Biogen Pulls EU Filing For Aduhelm But Stands By Alzheimer’s Drug

The marketing application was withdrawn before the European Medicines Agency had finished re-examining its earlier recommendation to reject the drug.

EU Aduhelm Filing: Biogen Faces Second High-Stakes Meeting At EMA

Biogen needs to explain why its Alzheimer’s disease drug should be approved in the EU, after the European Medicines Agency rejected the product last year.

European Countries Focus Horizon Scanning On Alzheimer’s Disease

Working out what’s on the horizon in terms of potential new treatments for Alzheimer’s disease should help countries prepare for the challenges that will be involved when it comes to determining patient access.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel